학술논문

Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2020, 31 pS974-pS975, 2p. Supplement: 4
Subject
Language
English
ISSN
15698041